Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Sarcopenia: still in relative definition-penia and severe treatment-penia..
Metabolism. 155717.
(2023). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013). The association between Helicobacter pylori infection and insulin resistance: a systematic review..
Helicobacter. 16(2), 79-88.
(2011). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name..
Metabolism. 113, 154413.
(2020). Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525..
Diabetes Care. 35(7), e53; author reply e54.
(2012). Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need..
Curr Med Res Opin. 38(6), 885-888.
(2022). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011). Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology..
J Clin Gastroenterol.
(2019). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016). Serum visfatin in nonalcoholic fatty liver disease..
Ann Hepatol. 13(1), 150-1.
(2013). Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). Bone and fat interplay in inflammatory bowel disease: clinical implications and future perspectives..
Inflamm Bowel Dis. 20(11), E22.
(2014). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics..
Metabolism. 92, 82-97.
(2019). Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease..
Curr Obes Rep.
(2024). Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists..
Metabolism. 66, 64-68.
(2017). Trying to treat diabetes in Greek crisis..
Int J Clin Pract. 66(5), 515.
(2012). Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid..
Arch Iran Med. 14(2), 149-51.
(2011). Histological alterations following thyroid fine needle biopsy: a systematic review..
Diagn Cytopathol. 37(6), 455-65.
(2009). Cilofexor for the Treatment of Nonalcoholic Steatohepatitis.
Curr Vasc Pharmacol.
(2021). Metabolism, Clinical and Experimental: seventy years young and growing..
Metabolism. 155333.
(2022).